echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > What are the results of high price special drugs?

    What are the results of high price special drugs?

    • Last Update: 2016-06-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medical geography 2016-06-27 Last year, many ministries and commissions including the national health and Family Planning Commission launched a price negotiation system for patent drugs and imported drugs, and selected patent drugs with high prices, heavy burden of disease and obvious benefits for patients as the negotiation pilot The core of the negotiation is through market methods such as volume for price or non market methods such as government R & D subsidies The actual price of patent drugs can meet the needs of drug manufacturers to continuously carry out innovative drug research The minimum need for hair On May 20 this year, the national health and Family Planning Commission announced the results of the first batch of national drug price negotiations Prices of three life-saving drugs, tenofovir dipivoxil for chronic hepatitis B and exetane and gefitinib for non-small cell lung cancer, were reduced by 67%, 54% and 55% respectively According to the PDB database of China Pharmaceutical Industry Information Center, by the first quarter of 2016, gefitinib's market sales trend was stable, and ektinib's growth momentum was strong Although the market share of tenofovir of GSK was not too large, the market potential was huge according to the growth breakthrough in the first quarter of this year Data source: China Pharmaceutical Industry Information Center PDB database high value drugs negotiations, how to play on the local? In Jiangsu Province, the provincial medical insurance agency shall establish a special drug review expert database to select and adjust the special drugs, determine the scope of new and adjusted special drugs, and establish a special drug negotiation directory The manufacturer shall apply to the medical insurance agency for special drugs to be included in the reimbursement scope of medical insurance negotiation, and provide evidence of clinical efficacy both at home and abroad The provincial medical insurance agency takes the lead in negotiating with the production enterprises on the settlement price of medical insurance, determining the payment rules of medical insurance treatment and drug donation rules, and the confirmed negotiation price is the unified settlement price of medical insurance in the whole province Medical geography learned that in a medical year, for example, the medical insurance fund and insured patients jointly bear the treatment cost of six bottles of Herceptin, and according to the medical insurance settlement price The insured patients can apply for charity assistance to the (charity) cooperative organization after the first medication, and enjoy the treatment of free drug supply period of follow-up treatment after the examination and approval of the (charity) cooperative organization In a medical year, China Cancer Foundation or Shanghai Roche Pharmaceutical Co., Ltd will provide no more than 8 bottles of Herceptin for insured patients according to relevant regulations of Herceptin assistance project After the use of 14 bottles of Herceptin, it is still necessary to increase the medication, and the remaining cost shall be paid by the patient himself What you see is game, what I see is win-win! Who said that the special medicine negotiation must be a battle with a knife and an axe to see the growth performance of Herceptin In Qingdao, Shandong Province, three main aspects of drugs are gradually selected: first, for incurable diseases such as malignant tumors Among the 26 special drugs in Qingdao, there are 11 anti-cancer drugs, accounting for a large proportion Second, drugs that can effectively treat rare diseases It's very expensive and hard to buy Third, specific drugs for specific local diseases In the second batch of special drugs and special materials rescue projects, Qingdao added 5 drugs to be selected to undergo the three standards of high clinical use cost, significant efficacy and difficult to use other treatment schemes to replace these three standards, and then entered the bidding negotiation, and finally formed a composite package mode of cost reduction, including price reduction, drug donation, management support, service support, training support, etc In fact, the exetane (Kemena) mentioned above has a textbook performance in the implementation of the special drug and special material rescue policy in Qingdao According to the relevant person in charge of Qingdao human resources and social security, the annual growth rates in 2012 and 2013 were 759.79% and 105.34% respectively Since 2014, the number of patients using Kemena has been basically stable, and the growth rate of sales began to slow down, with an average of 37.69% At the same time of the increase in sales, the number of drugs donated by enterprises to patients also increased year by year From 2011 to 2015, the total donation of Kemena was about 130.5108 million yuan, which benefited the vast number of patients According to the standard of serious illness treatment, the clear effect and strong voice of the masses, combined with the incidence rate and clinical curative effect, 62 kinds of drugs were recommended for the special drug negotiation in Zhejiang, Zhejiang The selection expert group selects 62 kinds of drugs, selects 31 kinds of drugs as the negotiation alternatives to ensure that the selected drugs have better pharmacoeconomic value, and another group of medical insurance and clinical experts conduct competitive negotiation with drug companies Finally, Xiaobian would like to say: generally, the negotiation of medical insurance drug access is mainly aimed at the drug price In addition to effectively reducing the drug price and expanding drug donation through negotiation, enterprises should also pay attention to the follow-up service support of medical insurance, such as monitoring the treatment effect of patients, training the skills of medical personnel and other follow-up service management, so as to provide technical support for clinical treatment in a timely manner Reasonable price concessions and a small amount of rescue funds can drive a lot of value-added.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.